ProQR's Japanese Axiomer Patent Upheld After Opposition
Ticker: PRQR · Form: 6-K · Filed: Feb 15, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: intellectual-property, patent, legal-update, biotechnology
TL;DR
**ProQR's key Japanese Axiomer™ patent was just upheld, securing their IP in a major market!**
AI Summary
ProQR Therapeutics N.V. announced on February 15, 2024, that its Japanese Axiomer™ Patent was upheld following an opposition. This successful defense of its intellectual property strengthens the company's position regarding its leading technology in Japan.
Why It Matters
The upholding of ProQR's Japanese Axiomer™ Patent strengthens its intellectual property portfolio and protects its leading technology in a key market, potentially enhancing its competitive position and future revenue streams.
Risk Assessment
Risk Level: low — The upholding of a key patent reduces intellectual property risk for ProQR Therapeutics N.V. and is generally a positive development.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — registrant
- ProQR (company) — registrant
- Japanese Axiomer™ Patent (other) — intellectual property
- February 15, 2024 (date) — date of press release and filing
FAQ
What is the name of the registrant filing this 6-K report?
The registrant is ProQR Therapeutics N.V.
What was the main subject of the press release issued by ProQR Therapeutics N.V. on February 15, 2024?
The press release announced that ProQR's Japanese Axiomer™ Patent was upheld following an opposition.
What is the Commission File Number for ProQR Therapeutics N.V.?
The Commission File Number is 001-36622.
What is the business address of ProQR Therapeutics N.V.?
The business address is Zernikedreef 9, 2333 CK Leiden, The Netherlands.
On what date did ProQR Therapeutics N.V. issue the press release mentioned in this filing?
ProQR Therapeutics N.V. issued the press release on February 15, 2024.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-02-15 07:46:54
Filing Documents
- tm246323d1_6k.htm (6-K) — 10KB
- tm246323d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-24-024357.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: February 15, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated February 15, 2024.